This undated electron microscope image made available by the U.S. National Institutes of Health in February 2020 shows the Novel Coronavirus SARS-CoV-2, yellow, emerging from the surface of cells, blue/pink, cultured in the lab. Also known as 2019-nCoV, the virus causes COVID-19. THE CANADIAN PRESS/AP, NIAID-RML

This undated electron microscope image made available by the U.S. National Institutes of Health in February 2020 shows the Novel Coronavirus SARS-CoV-2, yellow, emerging from the surface of cells, blue/pink, cultured in the lab. Also known as 2019-nCoV, the virus causes COVID-19. THE CANADIAN PRESS/AP, NIAID-RML

Canadian company urges human trials after COVID-19 vaccine results in mice

Providence Therapeutics says it needs federal funding to move forward

A Canadian company is telling the government today that its trials of a potential COVID-19 vaccine on animals completely blocked the virus, but it must conduct human trials to know whether it has found a possible cure for the pandemic.

And a leading health-care expert says the findings are promising even though they haven’t been peer-reviewed.

Providence Therapeutics says it needs federal funding to move forward, but it has not heard back from the Trudeau government since May, the month after submitting a $35-million proposal to conduct first-stage human trials.

Providence has told the government it could deliver five million doses of its new vaccine by mid-2021 for use in Canada if it were able to successfully complete human testing, but it has heard nothing.

Eric Marcusson, the San Francisco-based co-founder of Providence and its chief science officer, says the company has concluded testing on mice that showed its vaccine was able to block the entry of the novel coronavirus into their cells.

Successful tests in animals can provide proof of the concept behind a potential new medicine or vaccine before trials in ever-larger groups of human subjects determine how well the drug works in the body and whether it has harmful side-effects.

Trials in humans are expensive and usually time-consuming.

Mario Ostrowski, the University of Toronto professor of medicine and immunology whose laboratory performed the animal trials, said he supports the results and says they are on par with tests of vaccine candidates from the American pharmaceutical firm Moderna and Germany’s BioNTech.

All three companies use the same new mRNA vaccine technology and last week, Moderna began a 30,000-person human trial after receiving hundreds of millions of dollars from the U.S. government.

The U.S. has also committed to pay Germany’s BioNTech and its American partner Pfizer $1.95 billion to produce 100 million doses if their vaccine candidate proves safe and effective in humans.

The mRNA vaccine technology involves using a key fragment of genetic material instead of working with an inactive sample of live virus.

“We have been testing the prototype vaccine in animal studies,” Ostrowski told The Canadian Press. “When we give the vaccine to mice, it is safe and makes a very strong immune response and very potent antibodies.”

Ostrowski said that the strength of the antibodies found in the mice appeared to neutralize the virus better than other similar vaccine candidates have at the same testing stage.

“Another point is that the Providence vaccine is very similar to the Moderna vaccine in the U.S. and the German (BioNTech) vaccines, both showing excellent results,” added Ostrowski, who practices at St. Michael’s Hospital in Toronto.

READ MORE: Canada signs deals with Pfizer, Moderna to get doses of COVID-19 vaccines

Brad Wouters, the executive vice-president of the Toronto-based University Health Network, said he has seen the new Providence data and it looks promising, but it needs to be peer-reviewed.

“The fact that the vaccine has created neutralizing antibodies means that the mouse immune system is reacting to the vaccine and producing antibodies that block the ability of the virus to infect cells,” Wouters said in an emailed response to questions.

“This suggests the results are better than even they were expecting.”

But Wouters added that the Providence data needs a full peer review, and that under normal circumstances he wouldn’t even be commenting publicly on research at this stage unless it were accompanied by a published peer review.

“This is the normal and correct way for this to happen. But as you have seen, COVID-19 is breaking traditions and they (Providence) are certainly not the first to release information from experimental research in advance of publication,” said Wouters, who is also the senior scientist at the Princess Margaret Cancer Centre.

Alberta Sen. Doug Black has urged Ottawa to fund Providence so it can develop a domestic COVID-19 vaccine to lessen the risk Canadians will have wait in line for a foreign-made pandemic cure.

Several health-care professionals have also written to Innovation Minister Navdeep Bains to urge him to make up his mind on the Providence proposal.

The company plans to release the results publicly on Wednesday at the same time it delivers them to several relevant government departments.

“We’re still blocking the virus 100 per cent. Nothing gets in,” Marcusson said in a telephone interview from San Francisco, where he has been living in lockdown since March as the pandemic exploded in California.

“There’s no doubt this vaccine needs to be tested in humans because the results in mice are really that exceptional. This has the chance to be an extremely effective vaccine, but we won’t know for sure until we get into humans,” he said.

READ MORE: 30% of British Columbians would ‘wait and see’ before taking COVID vaccine: poll

Marcusson is a 20-year veteran of the American biotechnology sector and had founded his own consultant business before meeting Providence chief executive Brad Sorenson in 2014. The two founded Providence in 2015 to develop cancer vaccines but it has pivoted to COVID-19. Marcusson said 20 per cent of his work remains outside the company as a consultant.

Black and several health experts say the government must move forward with a made-in-Canada vaccine because there have been troubling signs that a vaccine produced abroad likely wouldn’t be available to Canadians until much later.

Canada has already funded a the partnership between China’s CanSino Biologics and Dalhousie University in Nova Scotia but China has held up shipments of the vaccine that it was supposed to send to Dalhousie researchers by the end of May to start human trials.

“They’ve already been burned a couple of times with masks not getting across the border from the U.S. and a vaccine that they helped fund not getting into the country because it was held up at customs in China,” said Marcusson.

“So, this is a vaccine that can be made in Canada for Canadians,” he added. “It would be nice if that wasn’t important, but it is important, and they need to realize this and fund a Canadian solution to this problem.”

Mike Blanchfield, The Canadian Press


Like us on Facebook and follow us on Twitter.

Want to support local journalism during the pandemic? Make a donation here.

CanadaCoronavirusvaccines

Get local stories you won't find anywhere else right to your inbox.
Sign up here

Just Posted

Kelowna City Hall. (Michael Rodriguez - Capital News)
Kelowna’s 2021 preliminary budget proposes 4.27% tax increase

Proposed budget calls for eight new RCMP officers

Good Samaritan Mountainview Village located at 1540 KLO Road in Kelowna. (Good Samaritan Society)
First long-term care resident dies from COVID-19 in Interior Health

Man in his 80s dies following virus outbreak at Mountainview Village

(File)
One death and 82 new cases of COVID-19 in Interior Health

1,981 total cases, 609 are active and those individuals are on isolation

The former BC Tree Fruits office building at 1473 Water Street has been sold. (Contributed)
BC Tree Fruits downtown Kelowna office sold for $7.5M

Historic building sold for 44 per cent more than the $5.2-million asking price

Vernon-North Okanagan RCMP was called to a report of a fight at an Okanagan Landing Halloween party Saturday, Oct. 31, but issued the homeowner a ticket  under the COVID-19 Related Measures Act for having too many people at the party. (Black Press file photo)
West Kelowna man, dog rescued from carbon monoxide poisoning

The man was quickly transported to the hospital

Motorists wait to enter a Fraser Health COVID-19 testing facility, in Surrey, B.C., on Monday, Nov. 9, 2020. THE CANADIAN PRESS/Darryl Dyck
Another 694 diagnosed with COVID-19 in B.C. Thursday

Three more health care outbreaks, 12 deaths

Police responded to W.L. Seaton Secondary after reports of young man attempting to smash car windows in the student parking lot on Wednesday, Sept. 25, 2019. (Facebook)
Case of COVID-19 at North Okanagan high school

Member of W.L. Seaton Secondary exposure Nov. 26

The aftermath of the 3 a.m. fire in Keremeos. (Keremeos Fire Department)
Fire and explosion wakes Keremeos residents

A motorhome was consumed and a boat severely damaged after the 3 a.m. fire

A demonstrator wears representations of sea lice outside the Fisheries and Oceans Canada offices in downtown Vancouver Sept. 24, demanding more action on the Cohen Commission recommendations to protect wild Fraser River sockeye. (Quinn Bender photo)
First Nations renew call to revoke salmon farm licences

Leadership council implores use of precautionary principle in Discovery Islands

Ten-month-old Aidan Deschamps poses for a photo with his parents Amanda Sully and Adam Deschamps in this undated handout photo. Ten-month-old Aidan Deschamps was the first baby in Canada to be diagnosed with spinal muscular atrophy through Ontario’s newborn screening program. The test was added to the program six days before he was born. THE CANADIAN PRESS/HO, Children’s Hospital Eastern Ontario *MANDATORY CREDIT*
First newborn tested for spinal muscular atrophy in Canada hits new milestones

‘If Aidan had been born any earlier or anywhere else our story would be quite different’

Margaret Holm
HOLM: Better Bicycle Lanes

Margaret Holm writes about solutions to global warming

The newly opened Switzmalph Child Care Centre at Salmon Arm offers culturally enriched programs featuring the Secwépemc culture but is open to children of all heritages. (Martha Wickett - Salmon Arm Observer)
Video: Switzmalph Child Care Centre shares culture with Shuswap community

New daycare at Salmon Arm offers Secwépemc culturally enriched programs to children of all heritages

Cannabis bought in British Columbia (Ashley Wadhwani/Black Press Media)
Is it time to start thinking about greener ways to package cannabis?

Packaging suppliers are still figuring eco-friendly and affordable packaging options that fit the mandates of Cannabis Regulations

Man walking in the winter downtown.
Dyer: The role of air tightness testing in energy efficiency

Kristy Dyer has a background in art and physics and consulted for Silicon Valley

Most Read